Drug Profile
Tefinostat - Chroma Therapeutics
Alternative Names: CHR-2845; Tefinostat tartrateLatest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Chroma Therapeutics
- Developer Cardiff University; Chroma Therapeutics
- Class Antineoplastics; Esters; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Inflammation
- No development reported Chronic myelomonocytic leukaemia; Haematological malignancies; Lymphoma
Most Recent Events
- 08 Sep 2021 No development reported - Phase-II for Chronic myelomonocytic leukaemia in United Kingdom (PO)
- 26 Jul 2019 Cardiff University completes the phase II MONOCLE trial in Chronic myelomonocytic leukaemia in United Kingdom (PO) (ISRCTN17394489) (EudraCT2015-002281-23)
- 01 Dec 2018 Efficacy and adverse events data from a phase II trial in Chronic myelomonocytic leukaemia presented at the 60th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2018)